Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 4.09
BIIB's Cash to Debt is ranked lower than
66% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. BIIB: 4.09 )
Ranked among companies with meaningful Cash to Debt only.
BIIB' s 10-Year Cash to Debt Range
Min: 0.25  Med: 1.56 Max: N/A
Current: 4.09
Equity to Asset 0.75
BIIB's Equity to Asset is ranked higher than
60% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. BIIB: 0.75 )
Ranked among companies with meaningful Equity to Asset only.
BIIB' s 10-Year Equity to Asset Range
Min: 0.52  Med: 0.75 Max: 0.84
Current: 0.75
0.52
0.84
Interest Coverage 134.09
BIIB's Interest Coverage is ranked lower than
83% of the 375 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. BIIB: 134.09 )
Ranked among companies with meaningful Interest Coverage only.
BIIB' s 10-Year Interest Coverage Range
Min: 2.3  Med: 36.19 Max: 9999.99
Current: 134.09
2.3
9999.99
F-Score: 9
Z-Score: 13.10
M-Score: -2.22
WACC vs ROIC
6.01%
36.55%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 10/10

vs
industry
vs
history
Operating margin (%) 45.12
BIIB's Operating margin (%) is ranked higher than
95% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. BIIB: 45.12 )
Ranked among companies with meaningful Operating margin (%) only.
BIIB' s 10-Year Operating margin (%) Range
Min: -128.05  Med: 31.63 Max: 52.91
Current: 45.12
-128.05
52.91
Net-margin (%) 33.89
BIIB's Net-margin (%) is ranked higher than
93% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. BIIB: 33.89 )
Ranked among companies with meaningful Net-margin (%) only.
BIIB' s 10-Year Net-margin (%) Range
Min: -128.85  Med: 21.74 Max: 36.64
Current: 33.89
-128.85
36.64
ROE (%) 31.71
BIIB's ROE (%) is ranked higher than
95% of the 761 Companies
in the Global Biotechnology industry.

( Industry Median: -29.50 vs. BIIB: 31.71 )
Ranked among companies with meaningful ROE (%) only.
BIIB' s 10-Year ROE (%) Range
Min: -21.44  Med: 17.31 Max: 31.98
Current: 31.71
-21.44
31.98
ROA (%) 23.93
BIIB's ROA (%) is ranked higher than
97% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -25.57 vs. BIIB: 23.93 )
Ranked among companies with meaningful ROA (%) only.
BIIB' s 10-Year ROA (%) Range
Min: -15.14  Med: 12.08 Max: 24.62
Current: 23.93
-15.14
24.62
ROC (Joel Greenblatt) (%) 189.05
BIIB's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -333.14 vs. BIIB: 189.05 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BIIB' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -62.49  Med: 68.87 Max: 211.79
Current: 189.05
-62.49
211.79
Revenue Growth (3Y)(%) 25.70
BIIB's Revenue Growth (3Y)(%) is ranked higher than
81% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. BIIB: 25.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BIIB' s 10-Year Revenue Growth (3Y)(%) Range
Min: -13.9  Med: 23.20 Max: 84.7
Current: 25.7
-13.9
84.7
EBITDA Growth (3Y)(%) 31.90
BIIB's EBITDA Growth (3Y)(%) is ranked higher than
84% of the 427 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. BIIB: 31.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BIIB' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -16.4  Med: 31.90 Max: 86
Current: 31.9
-16.4
86
EPS Growth (3Y)(%) 34.90
BIIB's EPS Growth (3Y)(%) is ranked higher than
87% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. BIIB: 34.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BIIB' s 10-Year EPS Growth (3Y)(%) Range
Min: -66  Med: 34.90 Max: 205.2
Current: 34.9
-66
205.2
» BIIB's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

BIIB Guru Trades in Q3 2014

Joel Greenblatt 31,391 sh (New)
Ray Dalio 1,646 sh (New)
Ken Heebner 80,000 sh (New)
Paul Tudor Jones 3,061 sh (+240.49%)
RS Investment Management 20,205 sh (+24.34%)
Mario Gabelli 4,635 sh (+11.02%)
Bill Frels 1,170 sh (+4.00%)
Frank Sands 4,952,096 sh (+1.24%)
Pioneer Investments 1,069 sh (unchged)
Stanley Druckenmiller 103,800 sh (unchged)
Steven Cohen Sold Out
Louis Moore Bacon Sold Out
Ron Baron 8,613 sh (-0.22%)
PRIMECAP Management 17,216,631 sh (-0.24%)
Murray Stahl 8,468 sh (-0.29%)
Jeremy Grantham 800,301 sh (-6.70%)
Ken Fisher 78,457 sh (-11.73%)
Jim Simons 92,661 sh (-28.31%)
Vanguard Health Care Fund 233,600 sh (-58.26%)
» More
Q4 2014

BIIB Guru Trades in Q4 2014

Pioneer Investments 18,593 sh (+1639.29%)
Ray Dalio 15,146 sh (+820.17%)
Paul Tudor Jones 27,786 sh (+807.74%)
Stanley Druckenmiller 359,400 sh (+246.24%)
Mario Gabelli 4,935 sh (+6.47%)
Ron Baron 9,144 sh (+6.17%)
Ken Fisher 79,254 sh (+1.02%)
Murray Stahl 8,517 sh (+0.58%)
Frank Sands 4,974,331 sh (+0.45%)
Frank Sands 4,974,331 sh (+0.45%)
Ken Heebner Sold Out
Vanguard Health Care Fund Sold Out
PRIMECAP Management 17,170,693 sh (-0.27%)
Bill Frels 1,140 sh (-2.56%)
Jeremy Grantham 696,116 sh (-13.02%)
Jim Simons 65,161 sh (-29.68%)
Joel Greenblatt 5,012 sh (-84.03%)
RS Investment Management 1,218 sh (-93.97%)
» More
Q1 2015

BIIB Guru Trades in Q1 2015

Vanguard Health Care Fund 339,100 sh (New)
Signature Select Canadian Fund 5,500 sh (New)
Steven Cohen 8,800 sh (New)
John Burbank 46,268 sh (New)
Richard Snow 2,500 sh (New)
RS Investment Management 27,197 sh (+2132.92%)
Ray Dalio 20,446 sh (+34.99%)
Ken Fisher 81,058 sh (+2.28%)
Frank Sands 5,009,615 sh (+0.71%)
Ron Baron 9,144 sh (unchged)
Joel Greenblatt Sold Out
Mario Gabelli 4,932 sh (-0.06%)
Pioneer Investments 18,472 sh (-0.65%)
Murray Stahl 8,448 sh (-0.81%)
Bill Frels 1,120 sh (-1.75%)
PRIMECAP Management 16,558,763 sh (-3.56%)
Jeremy Grantham 669,145 sh (-3.87%)
Stanley Druckenmiller 175,000 sh (-51.31%)
Jim Simons 30,300 sh (-53.50%)
Paul Tudor Jones 4,880 sh (-82.44%)
» More
Q2 2015

BIIB Guru Trades in Q2 2015

Vanguard Health Care Fund 1,780,330 sh (+425.02%)
Ken Fisher 80,932 sh (-0.16%)
» More
» Details

Insider Trades

Latest Guru Trades with BIIB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 21.09
BIIB's P/E(ttm) is ranked higher than
72% of the 215 Companies
in the Global Biotechnology industry.

( Industry Median: 41.60 vs. BIIB: 21.09 )
Ranked among companies with meaningful P/E(ttm) only.
BIIB' s 10-Year P/E(ttm) Range
Min: 11.74  Med: 28.86 Max: 1121.33
Current: 21.09
11.74
1121.33
Forward P/E 17.48
BIIB's Forward P/E is ranked higher than
78% of the 162 Companies
in the Global Biotechnology industry.

( Industry Median: 24.04 vs. BIIB: 17.48 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 20.90
BIIB's PE(NRI) is ranked higher than
73% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 39.20 vs. BIIB: 20.90 )
Ranked among companies with meaningful PE(NRI) only.
BIIB' s 10-Year PE(NRI) Range
Min: 11.73  Med: 28.85 Max: 1085.16
Current: 20.9
11.73
1085.16
P/B 5.88
BIIB's P/B is ranked lower than
60% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. BIIB: 5.88 )
Ranked among companies with meaningful P/B only.
BIIB' s 10-Year P/B Range
Min: 1.74  Med: 3.15 Max: 9.6
Current: 5.88
1.74
9.6
P/S 7.30
BIIB's P/S is ranked higher than
64% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 11.60 vs. BIIB: 7.30 )
Ranked among companies with meaningful P/S only.
BIIB' s 10-Year P/S Range
Min: 2.8  Med: 6.12 Max: 11.93
Current: 7.3
2.8
11.93
PFCF 22.87
BIIB's PFCF is ranked higher than
74% of the 144 Companies
in the Global Biotechnology industry.

( Industry Median: 45.01 vs. BIIB: 22.87 )
Ranked among companies with meaningful PFCF only.
BIIB' s 10-Year PFCF Range
Min: 10.04  Med: 23.65 Max: 169.92
Current: 22.87
10.04
169.92
POCF 20.37
BIIB's POCF is ranked higher than
75% of the 203 Companies
in the Global Biotechnology industry.

( Industry Median: 35.83 vs. BIIB: 20.37 )
Ranked among companies with meaningful POCF only.
BIIB' s 10-Year POCF Range
Min: 7.83  Med: 18.33 Max: 42.19
Current: 20.37
7.83
42.19
EV-to-EBIT 15.48
BIIB's EV-to-EBIT is ranked higher than
75% of the 224 Companies
in the Global Biotechnology industry.

( Industry Median: 32.56 vs. BIIB: 15.48 )
Ranked among companies with meaningful EV-to-EBIT only.
BIIB' s 10-Year EV-to-EBIT Range
Min: -21.4  Med: 20.85 Max: 585.7
Current: 15.48
-21.4
585.7
PEG 0.82
BIIB's PEG is ranked higher than
90% of the 73 Companies
in the Global Biotechnology industry.

( Industry Median: 2.63 vs. BIIB: 0.82 )
Ranked among companies with meaningful PEG only.
BIIB' s 10-Year PEG Range
Min: 0.33  Med: 1.21 Max: 2.56
Current: 0.82
0.33
2.56
Shiller P/E 41.01
BIIB's Shiller P/E is ranked higher than
60% of the 109 Companies
in the Global Biotechnology industry.

( Industry Median: 49.43 vs. BIIB: 41.01 )
Ranked among companies with meaningful Shiller P/E only.
BIIB' s 10-Year Shiller P/E Range
Min: 24.2  Med: 63.16 Max: 1337
Current: 41.01
24.2
1337
Current Ratio 2.20
BIIB's Current Ratio is ranked lower than
66% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. BIIB: 2.20 )
Ranked among companies with meaningful Current Ratio only.
BIIB' s 10-Year Current Ratio Range
Min: 0.78  Med: 3.47 Max: 17.39
Current: 2.2
0.78
17.39
Quick Ratio 1.86
BIIB's Quick Ratio is ranked lower than
67% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. BIIB: 1.86 )
Ranked among companies with meaningful Quick Ratio only.
BIIB' s 10-Year Quick Ratio Range
Min: 0.7  Med: 3.08 Max: 16.79
Current: 1.86
0.7
16.79
Days Inventory 241.46
BIIB's Days Inventory is ranked lower than
77% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 118.21 vs. BIIB: 241.46 )
Ranked among companies with meaningful Days Inventory only.
BIIB' s 10-Year Days Inventory Range
Min: 69.41  Med: 238.11 Max: 10720.03
Current: 241.46
69.41
10720.03
Days Sales Outstanding 46.46
BIIB's Days Sales Outstanding is ranked higher than
62% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. BIIB: 46.46 )
Ranked among companies with meaningful Days Sales Outstanding only.
BIIB' s 10-Year Days Sales Outstanding Range
Min: 4.44  Med: 45.99 Max: 106.69
Current: 46.46
4.44
106.69

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 52.43
BIIB's Price/Net Current Asset Value is ranked lower than
91% of the 538 Companies
in the Global Biotechnology industry.

( Industry Median: 7.59 vs. BIIB: 52.43 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
BIIB' s 10-Year Price/Net Current Asset Value Range
Min: 0.59  Med: 24.91 Max: 789.6
Current: 52.43
0.59
789.6
Price/Tangible Book 12.27
BIIB's Price/Tangible Book is ranked lower than
77% of the 687 Companies
in the Global Biotechnology industry.

( Industry Median: 5.90 vs. BIIB: 12.27 )
Ranked among companies with meaningful Price/Tangible Book only.
BIIB' s 10-Year Price/Tangible Book Range
Min: 0.41  Med: 6.51 Max: 48.16
Current: 12.27
0.41
48.16
Price/Projected FCF 2.51
BIIB's Price/Projected FCF is ranked higher than
70% of the 157 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. BIIB: 2.51 )
Ranked among companies with meaningful Price/Projected FCF only.
BIIB' s 10-Year Price/Projected FCF Range
Min: 0.65  Med: 2.06 Max: 25.99
Current: 2.51
0.65
25.99
Price/DCF (Earnings Based) 0.74
BIIB's Price/DCF (Earnings Based) is ranked higher than
93% of the 14 Companies
in the Global Biotechnology industry.

( Industry Median: 1.36 vs. BIIB: 0.74 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.20
BIIB's Price/Median PS Value is ranked higher than
52% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. BIIB: 1.20 )
Ranked among companies with meaningful Price/Median PS Value only.
BIIB' s 10-Year Price/Median PS Value Range
Min: 0.21  Med: 0.95 Max: 12.66
Current: 1.2
0.21
12.66
Price/Peter Lynch Fair Value 0.86
BIIB's Price/Peter Lynch Fair Value is ranked higher than
86% of the 49 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. BIIB: 0.86 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
BIIB' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.44  Med: 1.38 Max: 20.5
Current: 0.86
0.44
20.5
Price/Graham Number 3.43
BIIB's Price/Graham Number is ranked higher than
51% of the 171 Companies
in the Global Biotechnology industry.

( Industry Median: 3.52 vs. BIIB: 3.43 )
Ranked among companies with meaningful Price/Graham Number only.
BIIB' s 10-Year Price/Graham Number Range
Min: 0.43  Med: 3.25 Max: 21.27
Current: 3.43
0.43
21.27
Earnings Yield (Greenblatt) (%) 6.45
BIIB's Earnings Yield (Greenblatt) (%) is ranked higher than
93% of the 813 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. BIIB: 6.45 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BIIB' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.2  Med: 4.70 Max: 12
Current: 6.45
0.2
12
Forward Rate of Return (Yacktman) (%) 31.18
BIIB's Forward Rate of Return (Yacktman) (%) is ranked higher than
76% of the 88 Companies
in the Global Biotechnology industry.

( Industry Median: 14.22 vs. BIIB: 31.18 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
BIIB' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 0.8  Med: 20.20 Max: 43.9
Current: 31.18
0.8
43.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, CELG, CMXHY » details
Traded in other countries:IDP.Germany, BIIB.Mexico, BIIB.Switzerland, 0R1B.UK,
Biogen Idec Inc was formed as a California corporation in 1985 and became a Delaware corporation in 1985. The Company is a biotechnology company. It discovers, develops, manufactures and markets therapies for the treatment of autoimmune disorders, neurodegenerative diseases and hemophilia. It also collaborates on the development and commercialization of RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and other conditions. The Company's marketed products include MA Products, AVONEX; TYSABRI; RITUXAN; FAMPYRA; FUMADERM. The Company develop, manufacture and market a number of products designed to treat patients with MS. MS is a progressive neurological disease in which the body loses the ability to transmit messages along nerve cells, to a loss of muscle control, paralysis and, in some cases, death. AVONEX is one of the prescribed treatments for relapsing forms of MS. TYSABRI has advanced the treatment of relapsing MS with its established efficacy. TYSABRI is a monoclonal antibody approved in numerous countries as a monotherapy treatment for relapsing MS and also approved in the U.S. to treat Crohn's disease, an inflammatory disease of the intestines. RITUXAN is a prescribed monoclonal antibody therapeutic used to treat non-Hodgkin's lymphoma, rheumatoid arthritis, chronic lymphocytic leukemia and two forms of ANCA-associated vasculitis. FAMPYRA is the first treatment that addresses the unmet medical need of walking improvement in adult patients with MS who have walking disability. FAMPYRA is a prolonged-release tablet formulation of the drug fampridine. The Company is facing competition from other biotechnology firms and large pharmaceutical companies. The Company is subject to various federal and state laws pertaining to health care fraud and abuse, including anti-kickback laws and false claims laws.
» More Articles for NAS:BIIB

Headlines

Articles On GuruFocus.com
shortlist Jul 19 2015 
shortlist Jul 19 2015 
shortlist Jul 19 2015 
shortlist Jul 19 2015 
Investment Strategies for the Bullish Biotech Sector Jun 01 2015 
Apple, SunEdison and Biogen: Hellman, Jordan Management's Top 3 Stocks Outperform the Rise in the S& May 28 2015 
PRIMECAP Sells Portions of Its Top Two Stakes May 27 2015 
8 Top Healthcare Stocks to Watch May 13 2015 
Biogen Making A Breakthrough In Treating Alzheimer’s May 02 2015 
Vanguard Healthcare Fund Adds Four New Positions May 01 2015 

More From Other Websites
Tech and Biotech See Big-Time Insider Buying This Week – Apple, Biogen, Qualcomm and More Aug 01 2015
Biogen’s Experimental Alzheimer Therapy: Limited 2Q15 Success Jul 31 2015
These are the Biggest Risk to Biotech Jul 31 2015
Biogen: Positive 2Q15 Results for Multiple Sclerosis Pipeline Drugs Jul 31 2015
Key for Investors: Why Did Biotech Stocks Fall? Jul 31 2015
​How many multiple sclerosis patients are in the U.S.? No one knows. Jul 30 2015
Biogen Can Get Growth Spurt It Needs With Vertex Deal: Real M&A Jul 30 2015
BIOGEN INC. Financials Jul 30 2015
Biogen: Reports of Its Demise 'Have (Probably!) Been Greatly Exaggerated' Jul 30 2015
Biogen’s Hemophilia Portfolio: Growing Market Share in 2Q15 Jul 30 2015
The Zacks Analyst Blog Highlights: Biogen, AbbVie, Regeneron, Amgen and XOMA - Press Releases Jul 30 2015
Biogen’s Multiple Sclerosis Drugs Show 2Q15 Growth Jul 30 2015
​Sanofi calls out Genzyme, multiple sclerosis drug, as main drivers of growth again Jul 30 2015
​Here are all the Boston-area biotechs about to buy or get bought Jul 29 2015
Biotech Stock Roundup: Biogen Down on Tecfidera Issues, Regeneron's Praluent Gets FDA Nod - Analyst... Jul 29 2015
Four Reasons Gilead Can Head Higher Jul 29 2015
Biogen’s Weak 2Q15 Tecfidera Performance Dampens Sentiment Jul 29 2015
5 Stocks Insiders Love Right Now Jul 29 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK